• Something wrong with this record ?

Issues for the management of people with diabetes and COVID-19 in ICU

A. Ceriello, E. Standl, D. Catrinoiu, B. Itzhak, NM. Lalic, D. Rahelic, O. Schnell, J. Škrha, P. Valensi, “Diabetes and Cardiovascular Disease (D&CVD)” Study Group of the European Association for the Study of Diabetes (EASD),

. 2020 ; 19 (1) : 114. [pub] 20200720

Language English Country Great Britain

Document type Journal Article, Review

Persistent link   https://www.medvik.cz/link/bmc20024874

In the pandemic "Corona Virus Disease 2019" (COVID-19) people with diabetes have a high risk to require ICU admission. The management of diabetes in Intensive Care Unit is always challenging, however, when diabetes is present in COVID-19 the situation seems even more complicated. An optimal glycemic control, avoiding acute hyperglycemia, hypoglycemia and glycemic variability may significantly improve the outcome. In this case, intravenous insulin infusion with continuous glucose monitoring should be the choice. No evidence suggests stopping angiotensin-converting-enzyme inhibitors, angiotensin-renin-blockers or statins, even it has been suggested that they may increase the expression of Angiotensin-Converting-Enzyme-2 (ACE2) receptor, which is used by "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to penetrate into the cells. A real issue is the usefulness of several biomarkers, which have been suggested to be measured during the COVID-19. N-Terminal-pro-Brain Natriuretic-Peptide, D-dimer and hs-Troponin are often increased in diabetes. Their meaning in the case of diabetes and COVID-19 should be therefore very carefully evaluated. Even though we understand that in such a critical situation some of these requests are not so easy to implement, we believe that the best possible action to prevent a worse outcome is essential in any medical act.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20024874
003      
CZ-PrNML
005      
20201222153601.0
007      
ta
008      
201125s2020 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s12933-020-01089-2 $2 doi
035    __
$a (PubMed)32690029
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Ceriello, Antonio $u IRCCS MultiMedica, Via Gaudenzio Fantoli, 16/15, 20138, Milan, Italy. antonio.ceriello@hotmail.it.
245    10
$a Issues for the management of people with diabetes and COVID-19 in ICU / $c A. Ceriello, E. Standl, D. Catrinoiu, B. Itzhak, NM. Lalic, D. Rahelic, O. Schnell, J. Škrha, P. Valensi, “Diabetes and Cardiovascular Disease (D&CVD)” Study Group of the European Association for the Study of Diabetes (EASD),
520    9_
$a In the pandemic "Corona Virus Disease 2019" (COVID-19) people with diabetes have a high risk to require ICU admission. The management of diabetes in Intensive Care Unit is always challenging, however, when diabetes is present in COVID-19 the situation seems even more complicated. An optimal glycemic control, avoiding acute hyperglycemia, hypoglycemia and glycemic variability may significantly improve the outcome. In this case, intravenous insulin infusion with continuous glucose monitoring should be the choice. No evidence suggests stopping angiotensin-converting-enzyme inhibitors, angiotensin-renin-blockers or statins, even it has been suggested that they may increase the expression of Angiotensin-Converting-Enzyme-2 (ACE2) receptor, which is used by "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to penetrate into the cells. A real issue is the usefulness of several biomarkers, which have been suggested to be measured during the COVID-19. N-Terminal-pro-Brain Natriuretic-Peptide, D-dimer and hs-Troponin are often increased in diabetes. Their meaning in the case of diabetes and COVID-19 should be therefore very carefully evaluated. Even though we understand that in such a critical situation some of these requests are not so easy to implement, we believe that the best possible action to prevent a worse outcome is essential in any medical act.
650    _2
$a antihypertenziva $x terapeutické užití $7 D000959
650    _2
$a Betacoronavirus $x patogenita $7 D000073640
650    _2
$a biologické markery $x krev $7 D015415
650    _2
$a krevní glukóza $x účinky léků $x metabolismus $7 D001786
650    _2
$a koronavirové infekce $x diagnóza $x mortalita $x terapie $x virologie $7 D018352
650    _2
$a diabetes mellitus $x krev $x diagnóza $x farmakoterapie $x mortalita $7 D003920
650    _2
$a dyslipidemie $x farmakoterapie $x mortalita $7 D050171
650    _2
$a interakce hostitele a patogenu $7 D054884
650    _2
$a lidé $7 D006801
650    _2
$a statiny $x terapeutické užití $7 D019161
650    _2
$a hypertenze $x farmakoterapie $x mortalita $7 D006973
650    _2
$a hypoglykemika $x škodlivé účinky $x terapeutické užití $7 D007004
650    12
$a jednotky intenzivní péče $7 D007362
650    _2
$a pandemie $7 D058873
650    _2
$a virová pneumonie $x diagnóza $x mortalita $x terapie $x virologie $7 D011024
650    _2
$a hodnocení rizik $7 D018570
650    _2
$a rizikové faktory $7 D012307
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Standl, Eberhard $u Forschergruppe Diabetes e.V. at Munich Helmholtz Centre, Munich, Germany.
700    1_
$a Catrinoiu, Doina $u Clinical Center of Diabetes, Nutrition and Metabolic Diseases, Faculty of Medicine, Ovidius University of Constanta, Constanta, Romania.
700    1_
$a Itzhak, Baruch $u Clalit Health Services and Technion Faculty of Medicine, Haifa, Israel.
700    1_
$a Lalic, Nebojsa M $u Clinic for Endocrinology, Diabetes and Metabolic Diseases, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
700    1_
$a Rahelic, Dario $u Vuk Vrhovac University Clinic for Diabetes, Endocrinology and Metabolic Diseases, Merkur University Hospital, Zagreb, Croatia. University of Zagreb School of Medicine, Zagreb, Croatia. University of Osijek School of Medicine, Osijek, Croatia.
700    1_
$a Schnell, Oliver $u Forschergruppe Diabetes e.V. at Munich Helmholtz Centre, Munich, Germany.
700    1_
$a Škrha, Jan $u Department of Internal Medicine 3, 1st Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Valensi, Paul $u Unit of Endocrinology, Diabetology, Nutrition, Jean Verdier Hospital, APHP, Paris Nord University, Sorbonne Paris Cité, CINFO, CRNH-IdF, Bondy, France.
710    2_
$a “Diabetes and Cardiovascular Disease (D&CVD)” Study Group of the European Association for the Study of Diabetes (EASD)
773    0_
$w MED00008211 $t Cardiovascular diabetology $x 1475-2840 $g Roč. 19, č. 1 (2020), s. 114
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32690029 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201222153557 $b ABA008
999    __
$a ok $b bmc $g 1599019 $s 1115560
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 19 $c 1 $d 114 $e 20200720 $i 1475-2840 $m Cardiovascular diabetology $n Cardiovasc Diabetol $x MED00008211
LZP    __
$a Pubmed-20201125

Find record

Citation metrics

Archiving options